Oramed Pharmaceuticals Inc. (ORMP)
Nasdaq: ORMP · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2002
Grade5.3
◀ Past 6.0● Present 6.0▶ Future 4.3
Who owns Oramed Pharmaceuticals Inc.
As filed with the SECHolders of 5% or more
2
Nadav Kidron holds 7.6% of Common Stock par value $0.012 per share, as its SCHEDULE 13D/A filed Aug 28, 2025 says.
Directors and officers
8
report now, of 24 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Nadav Kidron
SCHEDULE 13D/A · filed Aug 28, 2025 · Common Stock par value $0.012 per share
Aquamarine Financial (Cayman) Ltd
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 5.06% in May 15, 2026
Leonard Braden Michael
SCHEDULE 13G/A · filed Jun 29, 2026 · Common Stock par value $0.012 per share · reported falling below 5%, from 8.3% in Feb 9, 2026
What ORMP reports owning in othersstakes of 5% or more, and other ties
Lifeward Ltd. LFWD
SCHEDULE 13D · filed May 14, 2026 · Ordinary Shares, no par value
Alpha Tau Medical Ltd. DRTS
SCHEDULE 13D · filed May 1, 2025 · Ordinary shares, no par value
Scilex Holding Company SCLX
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%
Nano Dimension Ltd. NNDM
SCHEDULE 13D/A · filed Jul 22, 2026 · Ordinary Shares, par value NIS 5.00 per share · reported falling below 5%
Other ties the annual report names
Alpha Tau
An entity · consolidated entity · owns, named in the 10-K filed Mar 26, 2026
Royalty Vest
An investee · investee · invested in, named in the 10-K filed Mar 26, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 26, 2026.
Insider tradesForm 4
4sales
0purchases
2sales on a scheduled plan
2people selling
$1.2Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 2, 2025 to Oct 2, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 2, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 24 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Hexter Joshua | COO & CBO | 2 | $700,000 | 1 | 0 | $0 |
| Gabay Avraham | Chief Financial Officer | 2 | $400,000 | 1 | 0 | $0 |